Business Context and Reporting Period
This Form 8-K is a current report filed by SELLAS Life Sciences Group, Inc. on January 11, 2018. The filing discloses the execution of a new employment agreement with John T. Burns, effective as of December 30, 2017.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation terms.
- Base Salary: $235,000 per year for the new Vice President, Finance and Corporate Controller.
- Annual Bonus: Eligible for up to 30% of base salary, subject to board discretion.
- Relocation Reimbursement: Up to $8,500 for reasonable expenses.
- Severance: Eligible for nine months of base salary (100%) upon termination without cause or resignation for good reason, commencing after the 18-month anniversary of the agreement.
Material Changes
The primary material change is the appointment of John T. Burns as Vice President, Finance and Corporate Controller, reporting to the Chief Financial Officer. This agreement supersedes Mr. Burns' previous severance and employment-related agreements with the company.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, market outlook, or discussion of general business risks. The only contingency noted is the specific severance provision triggered by termination without cause or resignation for good reason after the 18-month vesting period, contingent upon the employee's cooperation in winding up pending work.
Investor Verification Checklist
- Verify the full text of the Employment Agreement attached as Exhibit 10.1 for complete terms.
- Confirm the status of the stock option grant under the 2017 Equity Incentive Plan, as the specific number of shares is to be determined by the board.
- Review the company's cash position to assess the impact of the new salary and potential severance obligations.